Fludeoxyglucose (18F)

Generic Name: Fludeoxyglucose (18F)

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₁FO_₅

CAS Number: 63503-12-8

Unique Ingredient Identifier: 0Z5B2CJX4D

Background: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection.

Indication: The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.

Fludeoxyglucose F 18 Injection is indicated in positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnoses of cancer.

Associated Conditions: Cancer, Coronary Artery Disease (CAD), Epileptic seizure, Left Ventricular Dysfunction

Associated Therapies: -

Clinical Trials

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

Not Applicable

Recruiting

Conditions: Pulmonary Hypertension

Interventions: Drug: PET/MR with 18F-FDG

First Posted Date: 2021-05-26

Last Posted Date: 2024-08-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT04901884

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Phase 2

Conditions: Prostatic Cancer
Prostate Cancer
Prostate Neoplasms
Cancer Of Prostate
Metastatic Prostate Cancer

Interventions: Drug: 18F-DCFPyL
Drug: PSMA-11
Drug: 18F-FDG

First Posted Date: 2017-06-09

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 330

Registration Number: NCT03181867

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Prostate Cancer
Prostatic Cancer
Prostate Neoplasms
Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: 18F-NaF
Drug: 18F-DCFPyL
Drug: 18F-FDG

First Posted Date: 2017-06-02

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT03173924

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study

Not Applicable

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: 18-F FDG

First Posted Date: 2016-02-10

Last Posted Date: 2024-03-13

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 20

Registration Number: NCT02678884

Locations: 🇨🇦
University Health Network, Princess Margaret Cancer Center, Toronto, Ontario, Canada

Imaging of Intracerebral Inflammation in MS

Not Applicable

Completed

Conditions: Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: 18F-DPA-714 and 18F-FDG

First Posted Date: 2014-12-02

Last Posted Date: 2022-09-16

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 61

Registration Number: NCT02305264

Locations: 🇫🇷
Pitie Salpetriere Hospital, Paris, France
🇫🇷
Saint Antoine Hospital, Paris, France

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Conditions: Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: 18F-Fluoromisonidazole
Drug: Carboplatin
Procedure: Computed Tomography
Radiation: External Beam Radiation Therapy
Radiation: Image-Guided Adaptive Radiation Therapy
Drug: Fludeoxyglucose F-18
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Procedure: Positron Emission Tomography

First Posted Date: 2012-01-10

Last Posted Date: 2021-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 138

Registration Number: NCT01507428

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States

and more 28 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy